ENOVIS CORP (ENOV) Stock Fundamental Analysis
USA - NYSE:ENOV - US1940141062 - Common Stock
32.74 USD
+0.49 (+1.52%)
32.74 USD
0 (0%)
Overall ENOV gets a fundamental rating of 4 out of 10. We evaluated ENOV against 190 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of ENOV have multiple concerns. ENOV has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
ENOV had positive earnings in the past year.
In the past year ENOV had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: ENOV reported negative net income in multiple years.
Of the past 5 years ENOV 4 years had a positive operating cash flow.
1.2 Ratios
ENOV has a Return On Assets (-16.48%) which is comparable to the rest of the industry.
ENOV has a Return On Equity of -32.10%. This is comparable to the rest of the industry: ENOV outperforms 53.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.48% | ||
| ROE | -32.1% | ||
| ROIC | N/A |
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Operating Margin of ENOV has declined.
ENOV has a Gross Margin of 56.32%. This is comparable to the rest of the industry: ENOV outperforms 53.16% of its industry peers.
In the last couple of years the Gross Margin of ENOV has grown nicely.
The Profit Margin and Operating Margin are not available for ENOV so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.32% |
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
2. Health
2.1 Basic Checks
ENOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ENOV has been increased compared to 1 year ago.
The number of shares outstanding for ENOV has been increased compared to 5 years ago.
The debt/assets ratio for ENOV is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.95, we must say that ENOV is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.95, ENOV is in line with its industry, outperforming 48.42% of the companies in the same industry.
A Debt/Equity ratio of 0.53 indicates that ENOV is somewhat dependend on debt financing.
ENOV has a Debt to Equity ratio of 0.53. This is comparable to the rest of the industry: ENOV outperforms 40.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.95 |
ROIC/WACCN/A
WACC7.3%
2.3 Liquidity
ENOV has a Current Ratio of 2.25. This indicates that ENOV is financially healthy and has no problem in meeting its short term obligations.
ENOV has a Current ratio (2.25) which is in line with its industry peers.
A Quick Ratio of 1.15 indicates that ENOV should not have too much problems paying its short term obligations.
ENOV has a Quick ratio of 1.15. This is in the lower half of the industry: ENOV underperforms 70.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.25 | ||
| Quick Ratio | 1.15 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 34.01% over the past year.
ENOV shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -16.18% yearly.
Looking at the last year, ENOV shows a quite strong growth in Revenue. The Revenue has grown by 14.40% in the last year.
Measured over the past years, ENOV shows a decrease in Revenue. The Revenue has been decreasing by -8.73% on average per year.
EPS 1Y (TTM)34.01%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%27.42%
Revenue 1Y (TTM)14.4%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%7.5%
3.2 Future
ENOV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.19% yearly.
The Revenue is expected to grow by 8.87% on average over the next years. This is quite good.
EPS Next Y12.61%
EPS Next 2Y12.05%
EPS Next 3Y13.12%
EPS Next 5Y23.19%
Revenue Next Year7.28%
Revenue Next 2Y6.83%
Revenue Next 3Y6.79%
Revenue Next 5Y8.87%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ENOV is valuated reasonably with a Price/Earnings ratio of 9.89.
93.68% of the companies in the same industry are more expensive than ENOV, based on the Price/Earnings ratio.
ENOV is valuated cheaply when we compare the Price/Earnings ratio to 27.57, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 9.21, the valuation of ENOV can be described as very reasonable.
96.32% of the companies in the same industry are more expensive than ENOV, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.09, ENOV is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.89 | ||
| Fwd PE | 9.21 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ENOV indicates a rather cheap valuation: ENOV is cheaper than 87.37% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 11.29 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ENOV's earnings are expected to grow with 13.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.78
PEG (5Y)N/A
EPS Next 2Y12.05%
EPS Next 3Y13.12%
5. Dividend
5.1 Amount
ENOV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
32.74
+0.49 (+1.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners121.31%
Inst Owner Change-0.12%
Ins Owners1.19%
Ins Owner Change7.81%
Market Cap1.87B
Revenue(TTM)2.19B
Net Income(TTM)-827563000
Analysts83.53
Price Target55.42 (69.27%)
Short Float %12.32%
Short Ratio6.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.28%
Min EPS beat(2)6.8%
Max EPS beat(2)7.76%
EPS beat(4)4
Avg EPS beat(4)8.94%
Min EPS beat(4)4.97%
Max EPS beat(4)16.23%
EPS beat(8)8
Avg EPS beat(8)5.78%
EPS beat(12)12
Avg EPS beat(12)8.75%
EPS beat(16)15
Avg EPS beat(16)7.78%
Revenue beat(2)0
Avg Revenue beat(2)-1.09%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)-0.21%
Revenue beat(4)0
Avg Revenue beat(4)-1.21%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)-0.21%
Revenue beat(8)2
Avg Revenue beat(8)-0.97%
Revenue beat(12)4
Avg Revenue beat(12)-0.9%
Revenue beat(16)5
Avg Revenue beat(16)-8.66%
PT rev (1m)0%
PT rev (3m)-7.03%
EPS NQ rev (1m)-0.16%
EPS NQ rev (3m)-1.65%
EPS NY rev (1m)0%
EPS NY rev (3m)2.91%
Revenue NQ rev (1m)0.02%
Revenue NQ rev (3m)0.66%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.83%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.89 | ||
| Fwd PE | 9.21 | ||
| P/S | 0.85 | ||
| P/FCF | N/A | ||
| P/OCF | 9.95 | ||
| P/B | 0.73 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.29 |
EPS(TTM)3.31
EY10.11%
EPS(NY)3.55
Fwd EY10.85%
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)3.29
OCFY10.05%
SpS38.31
BVpS45.1
TBVpS-9.54
PEG (NY)0.78
PEG (5Y)N/A
Graham Number57.96
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.48% | ||
| ROE | -32.1% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.32% | ||
| FCFM | N/A |
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
F-Score3
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 4.85 | ||
| Cap/Depr | 66.53% | ||
| Cap/Sales | 8.77% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 66.47% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.25 | ||
| Quick Ratio | 1.15 | ||
| Altman-Z | 0.95 |
F-Score3
WACC7.3%
ROIC/WACCN/A
Cap/Depr(3y)55.91%
Cap/Depr(5y)50.8%
Cap/Sales(3y)7.49%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.01%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%27.42%
EPS Next Y12.61%
EPS Next 2Y12.05%
EPS Next 3Y13.12%
EPS Next 5Y23.19%
Revenue 1Y (TTM)14.4%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%7.5%
Revenue Next Year7.28%
Revenue Next 2Y6.83%
Revenue Next 3Y6.79%
Revenue Next 5Y8.87%
EBIT growth 1Y-155.23%
EBIT growth 3YN/A
EBIT growth 5Y-48.51%
EBIT Next Year74.87%
EBIT Next 3Y29.81%
EBIT Next 5Y28.11%
FCF growth 1Y96.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y889.17%
OCF growth 3Y-31.69%
OCF growth 5Y-2.82%